Effect of Probiotic Compound K11T e K11TMax in ASD

NCT ID: NCT06382909

Last Updated: 2024-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

505 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-22

Study Completion Date

2024-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research is characterized as a randomized, double-blind clinical trial (phase III) in which administered the probiotic K11-T (with and without added amino acids, fatty acids and vitamins) to children between 3 and 11 years old with Autism Spectrum Disorder - ASD, being subsequently assessed outcomes related to inflammatory markers and neuropsychiatric and sociopedagogical criteria. To this end, the study will create three groups, one of which will be a control group, which will receive a placebo, the other will receive the probiotic without micronutrients and another will receive the probiotic with added nutrients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the effectiveness of probiotic compounds K11-T and K11-Tmax (enriched with amino acids, acids fatty acids and vitamins), in its solid and nano-encapsulated formulation to improve the criteria neuropsychiatric, sociopedagogical and inflammatory disorders in children with ASD.

Secondary:

* Characterize the sample of individuals with ASD who will participate in the study through a questionnaire with sociodemographic and pedagogical data such as: Age in years; gender in percentage terms of the sample according to female or male; Weight in kg; Height in centimeters; Time since diagnosis of ASD in years and presence of psychiatric or neurological comorbidities in percentage terms of the sample.
* Investigate the association between probiotic consumption and neuropsychological results using the scale unit validated in the literature Vineland Adaptive Behavior Scales - Third Edition (Vineland-3) in the questionnaire format answered by parents/guardians of the child with ASD;
* Investigate the association between probiotic consumption and the change of psychiatric parameters through the application of the validated Autism Diagnostic Observation Schedule (ADOS) scale with children with ASD,
* Investigate the association between probiotic consumption and the change of psychopedagogical parameters using the Childhood Autism Rating Scale (CARS) validated in the literature, which will be answered by the teachers responsible for each child participating in the study;
* Analyze the possible effect of probiotics on inflammatory aspects in individuals with ASD, through serum (Insulin, C-Reactive Protein, Prolactin and Cortisol) and fecal (fecal calprotectin) biomarkers;
* Analyze the difference of using the K11-Tmax version, enriched with supplements, on the neuropsychological, psychiatric and psychopedagogical outcomes described above in comparison to the group that used K11-Tmax alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double blind, randomized, with placebo control
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mix Probiotic K11T with out vitamins

Drug-1: K11T

1 dose/day Orally

Group Type ACTIVE_COMPARATOR

Inflammatory level

Intervention Type DIETARY_SUPPLEMENT

Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage

Cognitive assessment

Intervention Type DIETARY_SUPPLEMENT

Neurological assessment Psychiatric assessment

Pedagogical assessment

Intervention Type DIETARY_SUPPLEMENT

Sociopedagogical assessment

Mix Probiotic K11TMAX with vitamins

Drug-1: K11Tmax

1 dose/day Orally

Group Type ACTIVE_COMPARATOR

Inflammatory level

Intervention Type DIETARY_SUPPLEMENT

Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage

Cognitive assessment

Intervention Type DIETARY_SUPPLEMENT

Neurological assessment Psychiatric assessment

Pedagogical assessment

Intervention Type DIETARY_SUPPLEMENT

Sociopedagogical assessment

Placebo drugs

Placebo

1 dose/day Orally

Group Type PLACEBO_COMPARATOR

Inflammatory level

Intervention Type DIETARY_SUPPLEMENT

Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage

Cognitive assessment

Intervention Type DIETARY_SUPPLEMENT

Neurological assessment Psychiatric assessment

Pedagogical assessment

Intervention Type DIETARY_SUPPLEMENT

Sociopedagogical assessment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inflammatory level

Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage

Intervention Type DIETARY_SUPPLEMENT

Cognitive assessment

Neurological assessment Psychiatric assessment

Intervention Type DIETARY_SUPPLEMENT

Pedagogical assessment

Sociopedagogical assessment

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteers must have a confirmed diagnosis of ASD carried out by qualified professionals, in accordance with the criteria established in the Diagnostic Manual and Statistics of Mental Disorders (DSM-5) or other diagnostic classification recognized.
* The study will include children and adolescents in the specific age range of 3 to 11years.
* Be regularly enrolled in a public or private school, or in a learning center special education.
* Absence of decompensated clinical or psychiatric comorbidities;
* Informed consent: Legal guardians must provide a informed consent, understanding the study objectives, procedures involved, the risks and benefits, as well as the freedom to withdraw from the study at any time. anytime.
* Informed Assent: Children ages 7 to 11 must provide an informed consent, understanding the objectives of the study, the procedures involved, the risks and benefits, as well as the freedom to withdraw from the study at any time. anytime.

Exclusion Criteria

* \- Concomitant restrictive medical conditions that may interfere with the results of the study, such as serious gastrointestinal diseases, significant metabolic diseases or immunodeficiencies.
* Use of specific medications such as broad-spectrum antibiotics or immunosuppressive medications during the follow-up period.
* Allergies or intolerances to components of the probiotics that will be administered.
* Previous or current participation in recent clinical studies with interventions different therapies.
* Uncontrolled heart conditions or serious unstable medical illnesses.
* Impossibility of being present on the pre-determined assessment dates clinics.
Minimum Eligible Age

3 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SENAI CIMATEC

OTHER

Sponsor Role collaborator

Deivis de Oliveira guimaraes

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Deivis de Oliveira guimaraes

Director of Research

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deivis O Guimaraes, PhD student

Role: STUDY_DIRECTOR

GON1 P&D

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gon1 gestora de Projetos

Vitória, Espírito Santo, Brazil

Site Status

Gon1 P&D

Vitória, Espírito Santo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Informed Consent Form

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.gon1.com.br

International Contract Research Organization

http://www.uvv.br

Ethics and research committee

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study on Probiotic Formula in Autistic Children
NCT06419530 NOT_YET_RECRUITING NA
Probiotic in Autism
NCT04939974 UNKNOWN NA